FDA’s Prasugrel Presentation To Advisory Committee Eases Doubts On Approvability
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA presentation put the advisory committee at ease with prasugrel’s benefit-risk profile and may have turned the tide toward approvability.
You may also be interested in...
Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.
Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.
Daiichi/Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
The frequency of cancer tumors seen in the prasugrel arm of Lilly/Daiichi Sankyo's TRITON trial was not enough to seriously concern a U.S. FDA advisory committee as the panel voted unanimously to recommend approval of the platelet inhibitor